Lensar Inc ( (LNSR) ) has released its Q3 earnings. Here is a breakdown of the information Lensar Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
LENSAR, Inc. is a global medical technology company specializing in advanced robotic laser solutions for cataract treatment, known for its ALLY Robotic Cataract Laser System which integrates AI and dual-modality laser technology. In its third quarter of 2025, LENSAR reported a 6% increase in revenue compared to the same period in 2024, driven by an 11% rise in worldwide procedure volume and a significant expansion of its ALLY Systems installed base. The company placed 18 new ALLY Systems, marking a 77% increase in its installed base over the previous year. Despite these gains, LENSAR faced a net loss of $3.7 million, largely attributed to acquisition-related expenses from its pending merger with Alcon. The company’s cash reserves decreased by $3.4 million during the quarter, leaving a balance of $16.9 million. Looking ahead, LENSAR remains focused on completing its acquisition by Alcon, expected in early 2026, while continuing to enhance its product offerings and operational efficiencies.